Clinical trials show diarrhea typically peaks during dose escalation and often resolves within 48 weeks as the body adapts, though some patients experience persistent symptoms requiring dose adjustment or medication formulation changes
In people with type 2 diabetes, this incretin effect is significantly reduced
6a), a model in which tirzepatide, semaglutide and retatrutide showed only modest ability to prevent the establishment of obesity 38,39
Exceptional evolutionary divergence of human muscle and brain metabolomes parallels human cognitive and physical uniqueness
Barbagallo M, Veronese N, Dominguez LJ
By year four, fewer than half of those who achieved clinically significant loss had maintained it